Construction of 3D cardiac tissue with synchronous powerful beating using human cardiomyocytes from human iPS cells prepared by a convenient differentiation method

Journal of Bioscience and Bioengineering
Yumi SasanoMitsuru Akashi

Abstract

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a new source of cardiac cells are expected to find use as tools in high-throughput screening for drug candidates and cardiotoxicity validation without the need for experimentation on animals. In recent years, it has been reported that drug screening using three-dimensional (3D) tissue is better than conventional 2D culture. Various methods have been developed for mass culture of hiPSC-CMs, and embryoid body (EB) formation is necessary in the majority of differentiation methods as this is reported to promote the differentiation of hiPSCs. However, these operations result in increased processing, cost and loss of hiPSCs. Here, we show alternative methods for differentiation to hiPSC-CMs from <100 μm hiPSC-clumps without EB formation and report on a 3D-tissue fabrication using hiPSC-CMs. The 3D cardiac tissue constructed by a layer-by-layer (LbL) cell coating technique (LbL-3D Heart) showed synchronous powerful beating. We conclude that this method enables cost-effective, reproducible and scalable hiPSC-CM production with high activity for tissue engineering, drug screening and regenerative medicine.

References

May 16, 2007·Angewandte Chemie·Michiya MatsusakiMitsuru Akashi
May 29, 2007·Nature Biotechnology·Kiichi WatanabeYoshiki Sasai
Dec 7, 2007·Nature Biotechnology·Masato NakagawaShinya Yamanaka
Mar 13, 2008·Tissue Engineering. Part a·Eun Jung LeeKevin D Costa
Feb 14, 2009·Nature Protocols·Juergen FriedrichLeoni A Kunz-Schughart
Dec 26, 2009·Stem Cell Research·Stefan R BraamChristine L Mummery
Mar 30, 2011·Trends in Cell Biology·Masatoshi Ohgushi, Yoshiki Sasai
Dec 31, 2009·World Journal of Stem Cells·Sasitorn RungarunlertAndras Dinnyes
Aug 16, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Megan N MurphyScott A Smith
Aug 20, 2011·Tissue Engineering. Part C, Methods·Tomohiro HayakawaTeruo Okano
Mar 31, 2012·Stem Cell Research·Vincent C ChenLarry A Couture
Jul 31, 2012·Biochemical and Biophysical Research Communications·Katsuhisa MatsuuraTeruo Okano
Jul 19, 2013·Proceedings of the National Academy of Sciences of the United States of America·Rie WadaMasaki Ieda
Apr 23, 2015·Stem Cells and Development·Giuseppe PettinatoNing Zhang
Apr 26, 2015·Journal of Pharmacological and Toxicological Methods·Keiichi AsakuraKohei Sawada
Aug 2, 2019·Biotechnology and Bioengineering·Shohei ChikaeMitsuru Akashi

❮ Previous
Next ❯

Citations

Jun 28, 2020·Journal of Tissue Engineering and Regenerative Medicine·Atsushi MiyaokaMitsuru Akashi
Mar 29, 2020·Scientific Reports·Yoshinari TsukamotoMitsuru Akashi
Jun 11, 2021·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Kota SuzukiYoshiki Sawa
Jul 1, 2021·Critical Reviews in Biotechnology·Amanda Marchini, Fabrizio Gelain
Aug 20, 2021·Frontiers in Bioengineering and Biotechnology·Nataliia Naumova, Laura Iop

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.